VivoSeq
Other

Cerebral Small Vessel Disease

17

Pipeline Programs↗

8

Active Trials↗

13

Companies Involved↗

Cerebral Small Vessel Disease is an emerging landscape with 17 programs across 13 companies. The most active players are AstraZeneca, Eli Lilly, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 11 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

11/100

Mech. Concentration

18/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedOtsuka logo

Otsuka

1 program

ApprovedV

Viatris Specialty LLC

1 program

ApprovedV

Validus Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

19 of 20 classified programs — the dominant modality here.

5%ALL OTHERSPeptide15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

17

clinical trials

Unknown status6 · 35%
Not yet recruiting5 · 29%
Completed3 · 18%
Recruiting2 · 12%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06715007·300 enrolled
Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease
Recruiting·IImperial College London·N/A·NCT06643013·106 enrolled
Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
Active, not recruiting·—·Phase 2·NCT05173896·100 enrolled
Investigation of Potential Mechanisms in Stellate Ganglion Block in Individuals With Cerebral Small Vessel Disease
Not yet recruiting·—·N/A·NCT06301711·80 enrolled
Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease
Not yet recruiting·—·N/A·NCT06319495·80 enrolled
Songling Xuemaikang Capsules for Cerebral Small Vessel Disease
Not yet recruiting·—·N/A·NCT07271732·90 enrolled
Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol
Not yet recruiting·FFirst Affiliated Hospital of Chengdu Medical College·Phase 4·NCT07180472·632 enrolled
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）
Not yet recruiting·FFudan University·Phase 4·NCT06061692·1,052 enrolled
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00163150·128 enrolled
Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease
Completed·—·N/A·NCT06176404·84 enrolled
Exploration of Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease
Completed·—·N/A·NCT06226415·84 enrolled
Remote Ischemic Conditioning on Cerebral Small Vessel Disease
Unknown status·—·N/A·NCT04816500·60 enrolled
Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)
Unknown status·—·Phase 4·NCT05583266·80 enrolled
Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
Unknown status·IInha University Hospital·Phase 4·NCT01932203·255 enrolled
Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients
Unknown status·—·Phase 4·NCT01819441·1,200 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)